Compare FGEN & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FGEN | ECOR |
|---|---|---|
| Founded | 1993 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.6M | 39.6M |
| IPO Year | 2014 | 2018 |
| Metric | FGEN | ECOR |
|---|---|---|
| Price | $8.36 | $4.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $146.50 | $25.50 |
| AVG Volume (30 Days) | 40.1K | ★ 57.6K |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 53.38 | N/A |
| Revenue | $8,298,000.00 | ★ $29,835,000.00 |
| Revenue This Year | N/A | $28.61 |
| Revenue Next Year | N/A | $41.21 |
| P/E Ratio | $0.16 | ★ N/A |
| Revenue Growth | N/A | ★ 27.90 |
| 52 Week Low | $4.85 | $4.16 |
| 52 Week High | $21.94 | $19.49 |
| Indicator | FGEN | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 38.19 | 46.32 |
| Support Level | $7.99 | $4.80 |
| Resistance Level | $8.55 | $5.11 |
| Average True Range (ATR) | 0.33 | 0.23 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 49.45 | 55.22 |
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.